
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Betsy Goodfellow | February 23, 2024 | News story | Research and Development | Almirall, Dermatology, Novo Nordisk, dermatology, monoclonal antibody
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk for the rights to its IL-21 blocking monoclonal antibody NN-8828. Almirall will obtain the rights to develop and commercialise the monoclonal antibody in certain indications, such as immune inflammatory dermatological diseases.
It is expected that Almirall will accelerate the development of this antibody in order to address key dermatological diseases, having responsibility for the global development and future commercialisation in these indications.
Under terms of the agreement, Novo Nordisk will receive an upfront payment as well as additional development and commercial milestone payments and royalties on future sales.
Dr Karl Ziegelbauer, chief scientific officer at Almirall, commented: “At Almirall, we are dedicated to developing the best possible treatments for patients suffering from skin diseases. This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pathway to effectively treat a range of dermatological diseases.”
Betsy Goodfellow
Related Content

Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …






